ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2426

Clinical Features and Outcomes of Immunoglobulin G4-Related Disease Including Kidney Involvement

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Author

  • Lee, Sua, Eulji University College of Medicine, Daejeon, Korea (the Republic of)
Background

Immunoglobulin G4-related disease (IgG4-RD) is a newly recognized disease, and a few epidemiologic studies about this disorder have been published. This research aimed to describe the clinical, laboratory, and histopathological features and outcomes of IgG4-RD.

Methods

Ninety-four patients who satisfied the comprehensive diagnostic criteria on IgG4-RD were included in this study. Fifty-eight (61.7%) were men. The mean age was 54.8 years, and the median follow-up duration was 32.9 months. The clinical feature between single and multiple organ involvement and with or without kidney involvement groups were evaluated based on symptoms and laboratory findings. The clinical outcome was assessed according to treatment strategies and response.

Results

Of 94 patients, 56 (59.6%) had multiple organs involvement. It showed a variety of symptoms and organs involved. Patients with multiple organ involvement had higher serum IgG and IgG4 levels than those with single organ involvement. Those with IgG4-related kidney disease (IgG4-RKD) had worse renal function. The incidence of peripheral blood eosinophilia and hypocomplementemia was higher in patients with renal involvement than in those without. Glucocorticoids-based therapy was most commonly used. (79.8%). Thirty-nine (41.5%) achieved complete remission. Eighteen (19.1%) relapsed after response to treatment. Eight (61.5%) of 13 patients with IgG4-RKD experienced improvement in renal function after treatment. None of the patients died during the follow-up period.

Conclusion

Kidney or other organ involvement is not significantly associated with clinical outcomes. Since IgG4-RD has different clinical features, it should be accurately diagnosed. Therefore, all physicians must actively diagnose and treat the condition.